Extended Data Table 1 Treatment-emergent AEs reported in at least 10% of patients. All emergent AEs described in the table were deemed at least possibly related to protocol-defined therapy

From: Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results